Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07174726 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa
A Phase 2 study of X-Linked Retinitis Pigmentosa (XLRP), sponsored by Beacon Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 6
- Study locations
NCT07174726: Recruiting Phase 2 study of X-Linked Retinitis Pigmentosa (XLRP), sponsored by Beacon Therapeutics.
NCT07174726 is a Phase 2 study of X-Linked Retinitis Pigmentosa (XLRP) that is actively recruiting participants, run by Beacon Therapeutics. The registered enrollment target is 10 participants. The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07174726, a Phase 2 study of X-Linked Retinitis Pigmentosa (XLRP), is actively recruiting participants, sponsored by Beacon Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this Phase 2 Study is to see if the investigational study drug, laruparetigene zovaparvovec, also known as AGTC-501, given in both eyes, is safe and works to preserve and/or improve vision and other symptoms of XLRP.
Conditions Studied
Interventions
- BIOLOGICAL Adeno-associated virus vector expressing a human RPGR gene
Study Locations (6)
Florida
- University of Florida Jacksonville Ophthalmology - Jacksonville
- Bascom Palmer Eye Institute - Miami
North Carolina
- Duke Eye Center - Durham
Ohio
- Cincinnati Eye Institute - Cincinnati
Oregon
- OHSU Casey Eye Institute - Portland
Texas
- Retina Foundation of the Southwest - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-09-10 |
| Est. Completion | 2030-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07174726
The ClinicalTrials.gov registry entry for NCT07174726 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beacon Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with X-Linked Retinitis Pigmentosa (XLRP) appearing as the primary indexed condition, and to 1 intervention - of which Adeno-associated virus vector expressing a human RPGR gene is the first listed.
NCT07174726 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Florida, North Carolina, Ohio.
Frequently Asked Questions
What is clinical trial NCT07174726 about?
NCT07174726 is a clinical study titled "A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa". The purpose of this Phase 2 Study is to see if the investigational study drug, laruparetigene zovaparvovec, also known as AGTC-501, given in both eyes, is safe and works to preserve and/or improve vision and other symptoms of XLRP.
What is the current status of trial NCT07174726?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2025-09-10. Estimated completion is 2030-12-15.
What conditions does trial NCT07174726 study?
This clinical trial studies the following conditions: X-Linked Retinitis Pigmentosa (XLRP).
What interventions are being tested in trial NCT07174726?
The interventions under investigation include: Adeno-associated virus vector expressing a human RPGR gene (BIOLOGICAL).
Who is sponsoring clinical trial NCT07174726?
This trial is sponsored by Beacon Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07174726 being conducted?
This trial has 6 study locations across Florida, North Carolina, Ohio, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.